Information Provided By:
Fly News Breaks for September 4, 2019
ONCY
Sep 4, 2019 | 08:33 EDT
Roth Capital analyst Jerry Isaacson started coverage of Oncolytics with a Buy rating and $6.80 price target given its "promising" oncolytic virus for multiple tumors. At this time, based on announced clinical plans, the analyst considers the company's lead product candidate pelareorep to have potential value in breast cancer, pancreatic cancer, and multiple myeloma, and sees potential for it to be approved in all of these indications in 2024.
News For ONCY From the Last 2 Days
There are no results for your query ONCY